JPRN-jRCT2031220333招募中3 期
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgaris
Tomoyuki Nishiura0 个研究点目标入组 240 人开始时间: 2022年9月13日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 9age old 至 <= 49age old（—）
- 性别
- All
入选标准
- •Patients with Acne vulgaris 9 to 49 years old
排除标准
- •(1)Patients with concurrent presense of serious cardiac, hepatic, renal, plumonary, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
- •(2)Patients with a history of hypersensitivity to investigational drug ingredients
- •(3)Pregnant or lactating women
研究者
相似试验
招募中
3 期
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgarisAcne vulgarisJPRN-jRCT2031220334Tomoyuki Nishiura40
进行中（未招募）
1 期
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerEUCTR2008-004672-50-ATovartis Pharma Services AG900
进行中（未招募）
1 期
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Advanced Ovarian Cancer (FIGO Stage II, Stage III, and Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer).MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-004672-50-DKGlaxoSmithKline Research & Development Ltd900
进行中（未招募）
1 期
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerAdvanced Ovarian Cancer (FIGO Stage II, Stage III, and Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer)MedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerEUCTR2008-004672-50-FRGlaxoSmithKline Research & Development Ltd900
进行中（未招募）
3 期
Efficacy and safety of pazopanib after first line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancerOvarian, fallopian tube or primary peritoneal cancerCancer - Ovarian and primary peritonealCancer - Other cancer typesACTRN12609000591257GlaxoSmithKline900